AbbVie (ABBV) announced that Alberta has added VRAYLAR® - cariprazine to its Health Drug Formulary, expanding public coverage for adults living with schizophrenia.
This milestone ensures that VRAYLAR® is now listed across all Canadian provinces and through federal programs such as NIHB, CSC, and VAC. Public drug plan access is crucial, as up to 90% of Canadians with serious mental illness are unemployed and rely on coverage to manage symptoms.
Experts highlighted the significance of this step in improving patient outcomes. Dr. Toba Oluboka, Clinical Professor of Psychiatry at the University of Calgary, noted that public reimbursement allows more patients to access tailored treatments that support daily stability and quality of life.
Chris Summerville, CEO of the Schizophrenia Society of Canada, praised the decision as the result of years of advocacy, calling it an important development for people managing schizophrenia.
AbbVie Canada's Vice-President and General Manager, Rami Fayed, emphasized the company's commitment to providing diverse therapeutic options and improving patient care nationwide.
VRAYLAR® is approved for treating schizophrenia in adults and as monotherapy for both manic and depressive episodes of bipolar I disorder. Jointly developed by AbbVie and Gedeon Richter Plc, it is commercialized by AbbVie across multiple global markets, including Canada.
ABBV currently trades at $216.92 or 0.65% lower on the NYSE.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.